Cases & Deals

  • Home
  • Practices
  • BioMarin asserts patent infringement claims against Dr. Reddy's Laboratories related to powder form of Kuvan®

Share

BioMarin asserts patent infringement claims against Dr. Reddy's Laboratories related to powder form of Kuvan®

August 2017

Client(s) BioMarin Pharmaceutical Inc.

Jones Day successfully represented BioMarin Pharmaceutical, Inc. in a patent infringement action against Dr. Reddy's Laboratories relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a powder form of generic versions of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU). A settlement was reached and the case dismissed.

BioMarin Pharmaceutical Inc. v. Dr. Reddy's Laboratories, Inc. et al., No. 3-17-cv-00774 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.